A phase I study of enzastaurin (ENZ), an oral PKC inhibitor, in combination with erlotinib (ERL) administered orally daily to patients with advanced solid malignancies Wakelee, H. A., Padda, S. K., Chhatwani, L., Pedro-Salcedo, M., Krupitskaya, Y., Musib, L., Latz, J. E. PERGAMON-ELSEVIER SCIENCE LTD. 2008: 126

View details for DOI 10.1016/S1359-6349(08)72335-8

View details for Web of Science ID 000261221200400